R C Crist1, G A Doyle2, K M Kampman3, W H Berrettini2. 1. Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, 19104, USA. Electronic address: crist@mail.med.upenn.edu. 2. Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, 19104, USA. 3. Treatment Research Center, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, 19104, USA.
Abstract
INTRODUCTION: An intronic polymorphism in the delta-opioid receptor gene (OPRD1) was previously associated with cocaine dependence in African-Americans. However, it is not known if the polymorphism (rs678849) is associated with dependence-related phenotypes within the cocaine dependent population. METHODS:Cocaine and alcohol dependent subjects were randomized to either topiramate or placebo. Abstinence from cocaine use was confirmed by urine drug screens for benzoylecgonine three times per week. Cocaine withdrawal and craving were assessed at randomization using the Cocaine Selective Severity Assessment (CSSA) and Minnesota Cocaine Craving Scale (MCCS), respectively. Subjects were also interviewed using the Addiction Severity Index (ASI). Genotype at rs678849 was determined for 105 African-American subjects and compared to cocaine abstinence, as well as scores for CSSA, MCCS, and ASI. RESULTS:African-American patients with the C/T or T/T genotypes (n=40) were more likely to be abstinent at the first urine drug screen and more likely to be abstinent for the week prior to randomization compared to patients with the C/C genotype (n=65). Subjects carrying the T allele were also more likely to have abstinent weeks over the course of the trial compared to those with the C/C genotype (RR=1.88, 95% CI=1.59-2.22, p=0.0035). No effects of rs678849 genotype on withdrawal, craving, or addiction severity were observed. CONCLUSIONS: A polymorphism in OPRD1 appears to be associated with both cocaine dependence and cocaine use during treatment in African-Americans. Follow-up studies to confirm the effect on cocaine use are warranted.
RCT Entities:
INTRODUCTION: An intronic polymorphism in the delta-opioid receptor gene (OPRD1) was previously associated with cocaine dependence in African-Americans. However, it is not known if the polymorphism (rs678849) is associated with dependence-related phenotypes within the cocaine dependent population. METHODS:Cocaine and alcohol dependent subjects were randomized to either topiramate or placebo. Abstinence from cocaine use was confirmed by urine drug screens for benzoylecgonine three times per week. Cocaine withdrawal and craving were assessed at randomization using the Cocaine Selective Severity Assessment (CSSA) and Minnesota Cocaine Craving Scale (MCCS), respectively. Subjects were also interviewed using the Addiction Severity Index (ASI). Genotype at rs678849 was determined for 105 African-American subjects and compared to cocaine abstinence, as well as scores for CSSA, MCCS, and ASI. RESULTS: African-American patients with the C/T or T/T genotypes (n=40) were more likely to be abstinent at the first urine drug screen and more likely to be abstinent for the week prior to randomization compared to patients with the C/C genotype (n=65). Subjects carrying the T allele were also more likely to have abstinent weeks over the course of the trial compared to those with the C/C genotype (RR=1.88, 95% CI=1.59-2.22, p=0.0035). No effects of rs678849 genotype on withdrawal, craving, or addiction severity were observed. CONCLUSIONS: A polymorphism in OPRD1 appears to be associated with both cocaine dependence and cocaine use during treatment in African-Americans. Follow-up studies to confirm the effect on cocaine use are warranted.
Authors: Timo Sarajärvi; Jussi T Tuusa; Annakaisa Haapasalo; Jarkko J Lackman; Raija Sormunen; Seppo Helisalmi; Johannes T Roehr; Antonio R Parrado; Petra Mäkinen; Lars Bertram; Hilkka Soininen; Rudolph E Tanzi; Ulla E Petäjä-Repo; Mikko Hiltunen Journal: Mol Cell Biol Date: 2011-04-04 Impact factor: 4.272
Authors: Florence F Roussotte; Neda Jahanshad; Derrek P Hibar; Elizabeth R Sowell; Omid Kohannim; Marina Barysheva; Narelle K Hansell; Katie L McMahon; Greig I de Zubicaray; Grant W Montgomery; Nicholas G Martin; Margaret J Wright; Arthur W Toga; Clifford R Jack; Michael W Weiner; Paul M Thompson Journal: Hum Brain Mapp Date: 2013-02-21 Impact factor: 5.038
Authors: Richard C Crist; Toni-Kim Clarke; Alfonso Ang; Lisa M Ambrose-Lanci; Falk W Lohoff; Andrew J Saxon; Walter Ling; Maureen P Hillhouse; R Douglas Bruce; George Woody; Wade H Berrettini Journal: Neuropsychopharmacology Date: 2013-04-23 Impact factor: 7.853
Authors: K M Kampman; J R Volpicelli; D E McGinnis; A I Alterman; R M Weinrieb; L D'Angelo; L E Epperson Journal: Addict Behav Date: 1998 Jul-Aug Impact factor: 3.913
Authors: Kyle M Kampman; Helen M Pettinati; Kevin G Lynch; Kelly Spratt; Michael R Wierzbicki; Charles P O'Brien Journal: Drug Alcohol Depend Date: 2013-06-28 Impact factor: 4.492
Authors: Toni-Kim Clarke; Andrew H Smith; Joel Gelernter; Henry R Kranzler; Lindsay A Farrer; Lynsey S Hall; Ana M Fernandez-Pujals; Donald J MacIntyre; Blair H Smith; Lynne J Hocking; Sandosh Padmanabhan; Caroline Hayward; Pippa A Thomson; David J Porteous; Ian J Deary; Andrew M McIntosh Journal: Addict Biol Date: 2015-04-10 Impact factor: 4.280
Authors: R Christopher Pierce; Bruno Fant; Sarah E Swinford-Jackson; Elizabeth A Heller; Wade H Berrettini; Mathieu E Wimmer Journal: Neuropsychopharmacology Date: 2018-02-05 Impact factor: 7.853